-+ 0.00%
-+ 0.00%
-+ 0.00%

Optimi Health plans Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD

PUBT·09/16/2026 12:25:35
Listen to the news
Optimi Health plans Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD
  • Optimi Health outlined plans to start a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD in 2027.
  • Results have not been presented; data are expected in the future once enrollment and follow-up are completed.
  • The study targets up to 100 participants across Canadian sites, focusing on veterans and frontline workers.
  • The trial aims to determine whether supervised MDMA-assisted psychotherapy can reduce PTSD symptoms versus baseline.
  • MDMA-assisted therapy remains investigational in Canada; Optimi’s MDMA products lack Health Canada market authorization.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160825PRIMZONEFULLFEED9827954) on September 16, 2026, and is solely responsible for the information contained therein.